MOLECULAR ASPECTS OF SARCOPENIA PATHOGENESIS IN CHRONOC KIDNEY DISEASE: INTEGRATED ROLE OF mTOR
https://doi.org/10.24884/1561-6274-2018-22-5-9-16
Abstract
In recent decades, the main pathogenetic mechanisms for maintaining muscle mass and strength have been discovered. Most of the scientific papers on the molecular aspects of the pathogenesis of sarcopenia were focused on the Akt-signaling pathway. The subject of the study were people of elderly and senile age, immobilized patients, patients with CKD 1-4 stages, animals. However, recently more attention has been paid to the role of protein – the mammalian target of rapamycin mTOR. It seems to be a key link in the control of muscle mass and is a promising marker in understanding the mechanisms of the pathogenesis of sarcopenia. Its importance in protein metabolism in patients with end stage kidney disease is not studied and requires further research. The presented scientific review contains information on the role of mTOR and its components – mTORC1 and mTORC2 in maintaining muscle mass and strength in a healthy person and in the formation of sarcopenia in patients with CKD. The general aid of mTORC1 complex is regulation of protein production which is necessary for cell growth and differentiation. mTORC2 complex functions are not enough studied. It is established that it plays important role in such biological processes as cytoskeleton organization, intracellular homeostasis maintaining, so it provides cell resistance and cell survivability in negative external and internal impulses. mTOR protein can be considered as promising molecular marker in diagnostics of protein metabolism early disturbances in patients with CKD and also as additory factor of sarcopenia severity assessment.
About the Author
M. Z. Gasanov
Rostov State Medical University
Russian Federation
Russian Federation
Department of Internal Medicine №1
Russia 344022, Rostov-on-Don, 29 Nakhichevansky Ln
Associate prof. Mitkhat Z.Gasanov, MD, PhD
Phone: +7(988)9473750
References
1. Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney inter Suppl 2013; 3: 1–150
2. Смирнов АВ, Добронравов ВА, Каюков ИГ. Кардиоренальный континуум: патогенетические основы превентивной нефрологии. Нефрология 2005; 9(3): 7-15 [Smirnov AV, Dobronravov VA, Kayukov IG. Cardio-Renal Continuum: Pathogenetic Basics of Preventive Nephrology. Nephrology 2005; 9(3): 7-15 (In Russ.)]
3. Смирнов АВ, Каюков ИГ, Добронравов ВА. Концепция факторов риска в нефрологии: Вопросы профилактики и лечения хронической болезни почек. Нефрология 2008; 12(1): 7-13 [Smirnov AV, Kayukov IG, Dobronravov VA. The concept of risk factors in nephrology: Prevention and treatment of chronic kidney disease. Nephrology (Saint- Petersburg). 2008; 12 (1): 7-13 (In Russ.)]
4. Смирнов АВ, Румянцев АШ, Добронравов В А, Каюков ИГ. XXI век – время интегративной нефрологии. Нефрология 2015; 19(2): 22-26 [Smirnov AV, Rumyantsev ASh, Dobronravov VA, Kayukov IG. XXI century – is the time of integrative nephrology Nephrology (Saint-Petersburg). 2015; 19 (2): 22-26 (In Russ.)]
5. Souza VA, Oliveira D, Barbosa SR et al. Sarcopenia in patients with chronic kidney disease not yet on dialysis: Analysis of the prevalence and associated factors. PLoS One 2017; 12(4):e0176230. doi: 10.1371/journal.pone.0176230
6. Ebner N, von Haehling S. Silver linings on the horizon: highlights from the 10th Cachexia Conference. J Cachexia Sarcopenia Muscle 2018; 9(1):176-182. doi: 10.1002/jcsm.12290
7. Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010; 39(4):412-423. doi: 10.1093/ageing/afq034
8. Robinder JS Dhillon, Sarfaraz Hasni. Pathogenesis and Management of Sarcopenia. Clin Geriatr Med 2017; 33(1): 17–26 doi: 10.1016/j.cger.2016.08.002
9. Leenders M, Verdijk LB, van der Hoeven L et al. Patients with type 2 diabetes show a greater decline in muscle mass, muscle strength, and functional capacity with aging. J Am Med Dir Assoc 2013; 14(8):585-592. doi: 10.1016/j.jamda.2013.02.006
10. Kim KS, Park KS, Kim MJ et al. Type 2 diabetes is associated with low muscle mass in older adults. Geriatr Gerontol Int 2014; 14(Suppl 1):115-121. doi: 10.1111/ggi.12189
11. Смирнов АВ, Румянцев АШ. Реабилитация больных на гемодиализе: руководство для врачей. CИМК, М., 2018: 208 [Smirnov AV, Rumyantsev ASh. Rehabilitation of patients on hemodialysis: a guide for physicians. Special Publishing House of Medical Books, Moscow, 2018: 208 (In Russ.)]
12. Morley JE, Anker SD, von Haehling S. Prevalence, incidence, and clinical impact of sarcopenia: Facts, numbers, and epidemiology-update 2014. J Cachexia Sarcopenia Muscle 2014; 5(4):253-259. doi: 10.1007/s13539-014-0161-y
13. Avan Aihie Sayer, Sian M. Robinson, Harnish P. Patel et al. New horizons in the pathogenesis, diagnosis and management of sarcopenia. Age Ageing 2013; 42(2):145–150. doi: 10.1093/ageing/afs191
14. Enoki Y, Watanabe H, Arake R et al. Indoxyl sulfate potentiates skeletal muscle atrophy by inducing the oxidative stressmediated expression of myostatin and atrogin-1. Sci Rep 2016; 6:32084. doi: 10.1038/srep32084
15. Moorthi RN, Avin KG. Clinical relevance of sarcopenia in chronic kidney disease. Curr Opin Nephrol Hypertens 2017; 26(3):219-228. doi: 10.1097/MNH.0000000000000318
16. Lenoir O, Tharaux PL, Huber TB. Autophagy in kidney disease and aging: lessons from rodent models. Kidney Int 2016; 90(5):950-964. doi: 10.1016/j.kint.2016.04.014
17. Яковенко АА, Румянцев АШ, Есаян АМ. Новые подходы к коррекции недостаточности питания больных, получающих лечение хроническим гемодиализом. Клиническая нефрология 2016; (3-4):42-45 [Yakovenko AA, Rumyantsev ASh, Yesayan AM. New approaches to correcting malnutrition in patients receiving chronic hemodialysis. Clinical nephrology 2016; (3-4): 42-45 (In Russ.)]
18. Смирнов АВ, Голубев РВ, Коростелева НЮ, Румянцев АШ. Снижение физической работоспособности у больных, получающих заместительную почечную терапию: фокус на саркопению. Нефрология 2017;21(4):9-29. doi:10.24884/1561- 6274-2017-21-4- 9-29 [Smirnov AV, Golubev RV, Korosteleva NY, Rumyantsev AS. Decline of physical performance in patients receiving renal replacement therapy: focus on sarcopenia. Nephrology (Saint-Petersburg). 2017;21(4):9-29 (In Russ.) doi: 10.24884/1561-6274-2017-21-4-9-29]
19. Вишневский КА, Румянцев АШ, Смирнов АВ, Коростелева НЮ. Возможности применения накожной билатеральной электромиостимуляции: от космической медицины к реабилитации инвалидов. Нефрология 2015; 19 (1): 41-53 [Vishnevskii KA, Rumyantsev AS, Smirnov AV, Korosteleva NY. Applicabilities of bilateral epicutaneous electromyostimulation: from space medicine to rehabilitation of disabled persons. Nephrology (Saint- Petersburg). 2015;19(1):41-53 (In Russ.)]
20. Wang XH, Mitch WE. Mechanisms of muscle wasting in chronic kidney disease. Nat Rev Nephrol 2014; 10(9):504-516. doi: 10.1038/nrneph.2014.112
21. Izumiya Y, Hopkins T, Morris C et al. Fast/Glycolytic muscle fiber growth reduces fat mass and improves metabolic parameters in obese mice. Cell Metab 2008; 7:159–172. doi: 10.1016/j.cmet.2007.11.003
22. McCarthy JJ and Esser KA. Anabolic and catabolic pathways regulating skeletal muscle mass. Curr Opin Clin Nutr Metab Care 2010; 13:230–235. doi: 10.1097/MCO.0b013e32833781b5
23. Glass DJ. Molecular mechanisms modulating muscle mass. Trends Mol Med 2003; 9:344– 350. doi: 10.1016/S1471-4914(03)00138-2
24. Hornberger TA. Mechanotransduction and the regulation of mTORC1 signaling in skeletal muscle. Int J Biochem Cell Biol 2011; 43:1267–1276. doi: 10.1016/j.biocel.2011.05.007
25. Glass DJ. Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol 2005; 37:1974–1984. doi: 10.1016/j.biocel.2005.04.018
26. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149:274–293. doi: 10.1016/j.cell.2012.03.017
27. Castets P, Lin S, Rion N et al. Sustained activation of mTORC1 in skeletal muscle inhibits constitutive and starvationinduced autophagy and causes a severe, late-onset myopathy. Cell Metab 2013; 17(5):731-744. doi: 10.1016/j.cmet.2013.03.015
28. Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 2011; 13(2):132-141. doi: 10.1038/ncb2152
29. Kawamata T, Kamada Y, Kabeya Y et al. Organization of the preautophagosomal structure responsible for autophagosome formation. Mol Biol Cell 2008; 19(5):2039-2050. doi: 10.1091/mbc.E07-10-1048
30. Alvers AL, Wood MS, Hu D et al. Autophagy is required for extension of yeast chronological life span by rapamycin. Autophagy 2009; 5(6):847-849
31. Settembre C, Zoncu R, Medina DL et al. A lysosome-tonucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J 2012; 31(5):1095-1108. doi: 10.1038/emboj.2012.32
32. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009; 10:307–318. doi: 10.1038/nrm2672
33. Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci 2009; 122(Pt 20):3589-3594. doi: 10.1242/jcs.051011
34. Yoon MS. The Role of Mammalian Target of Rapamycin (mTOR) in Insulin Signaling. Nutrients 2017; 9(11). pii: E1176. doi: 10.3390/nu9111176
35. Yoon MS. mTOR as a Key Regulator in Maintaining Skeletal Muscle Mass. Front Physiol 2017; 8:788. doi: 10.3389/fphys.2017.00788
36. Walston JD. Sarcopenia in older adults. Curr Opin Rheumatol 2012; 24:623–627. doi: 10.1097/BOR.0b013e328358d59b
37. Leger B, Derave W, De Bock K et al. Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation. Rejuvenat Res 2008; 11:163B– 175B. doi: 10.1089/rej.2007.0588
38. Mayer C, Zhao J, Yuan X. et al. mTOR-dependent activation of the transcription factor TIFIA links rRNA synthesis to nutrient availability. Genes Dev 2004; 18(4):423-434. doi: 10.1101/gad.285504
39. Hanaoka BY, Peterson CA, Horbinski C et al. Implications of glucocorticoid therapy in idiopathic inflammatory myopathies. Nat Rev Rheumatol 2012; 8(8):448-457. doi: 10.1038/nrrheum.2012.85.
40. Tonshoff B, Blum WF, Wingen AM, Mehls O. Serum insulinlike growth factors (IGFs) and IGF binding proteins 1, 2, and 3 in children with chronic renal failure: relationship to height and glomerular filtration rate. The European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood. J Clin Endocrinol Metab 1995; 80(9):2684-2691. doi: 10.1210/jcem.80.9.7545697
41. Ulinski T, Mohan S, Kiepe D, et al. Serum insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 in children with chronic renal failure: relationship to growth and glomerular filtration rate. The European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood. German Study Group for Growth Hormone Treatment in Chronic Renal Failure. Pediatr Nephrol 2000; 14(7):589-597
42. Powell DR, Liu F, Baker BK et al. Insulin-like growth factorbinding protein-6 levels are elevated in serum of children with chronic renal failure: a report of the Southwest Pediatric Nephrology Study Group. J Clin Endocrinol Metab 1997; 82(9): 2978-2984. doi: 10.1210/jcem.82.9.4215
43. Bach LA, Hale LJ. Insulin-like growth factors and kidney disease. Am J Kidney Dis 2015; 65(2):327-336. doi: 10.1053/j.ajkd.2014.05.024.
44. Feldt-Rasmussen B, El Nahas M. Potential role of growth factors with particular focus on growth hormone and insulin-like growth factor-1 in the management of chronic kidney disease. Semin Nephrol 2009; 29(1):50-58. doi: 10.1016/j.semnephrol.2008.10.007
45. Gu LJ, Zhang YY, Wang L et al. Changes of insulin-like growth factor 1 axis in chronic kidney disease and its role in skeletal muscle atrophy. Zhonghua Yi Xue Za Zhi 2018; 98(10):749-754. doi: 10.3760/cma.j.issn.0376-2491.2018.10.007
46. Oh WJ, Jacinto E. mTOR complex 2 signaling and functions. Cell Cycle. 2011; 10(14):2305-2316. doi: 10.4161/cc.10.14.16586
47. Yano S, Nagai A, Isomura M. et al. Relationship between Blood Myostatin Levels and Kidney Function:Shimane CoHRE Study. PLoS One 2015; 10(10):e0141035. doi: 10.1371/journal.pone.0141035
48. Sandri M. Protein breakdown in muscle wasting: role of autophagy-lysosome and ubiquitin-proteasome. Int J Biochem Cell Biol 2013; 45(10):2121-2129. doi: 10.1016/j.biocel.2013.04.023
49. Fan J, Kou X, Jia S et al. Autophagy as a Potential Target for Sarcopenia. J Cell Physiol 2016; 231(7):1450-1459. doi: 10.1002/jcp.25260
50. Han HQ, Zhou X, Mitch WE, Goldberg AL. Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. Int J Biochem Cell Bio. 2013; 45(10):2333-2347. doi: 10.1016/j.biocel.2013.05.019
51. Zhang L, Pan, J, Dong Y et al. Stat3 activation links a C/EBPδ to myostatin pathway to stimulate loss of muscle mass. Cell Metab 2013; 18(3):368-379. doi: 10.1016/j.cmet.2013.07.012
52. Itoh Y, Saitoh M, Miyazawa K. Smad3-STAT3 crosstalk in pathophysiological contexts. Acta Biochim Biophys Sin (Shanghai) 2018; 50(1):82-90. doi: 10.1093/abbs/gmx118
53. Mao S, Zhang J. Role of autophagy in chronic kidney diseases. Int J Clin Exp Med 2015; 8(12):22022-22029
54. Wang DT, Yang YJ, Huang RH et al. Myostatin activates the ubiquitin-proteasome and autophagy-lysosome systems contributing to muscle wasting in chronic kidney disease. Oxid Med Cell Longev 2015; 2015:684965. doi: 10.1155/2015/684965
55. Sharma M, McFarlane C, Kambadur R. et al. Myostatin: expanding horizons. IUBMB Life 2015; 67(8):589-600. doi: 10.1002/iub.1392
56. Trendelenburg, AU, Meyer A, Rohner D et al. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am J Physiol Cell Physiol 2009; 296(6):C1258–1270. doi: 10.1152/ajpcell.00105.2009
57. Zhang L, Rajan V, Lin E et al. Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J 2011; 25(5):1653-1663. doi: 10.1096/fj.10-176917
58. Sartori R, Milan G, Patron M et al. Smad2 and 3 transcription factors control muscle mass in adulthood. Am J Physiol Cell Physiol 2009; 296(6):C1248-1257. doi: 10.1152/ajpcell.00104.2009
59. Lee SW, Dai G, Hu Z et al. Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitinproteasome systems by phosphatidylinositol 3 kinase. J Am Soc Nephrol 2004; 15:1537–1545
60. Deger SM, Hung AM, Gamboa JL. Systemic inflammation is associated with exaggerated skeletal muscle protein catabolism in maintenance hemodialysis patients. JCI Insight 2017; 2(22). pii: 95185. doi: 10.1172/jci.insight.95185
Review
For citations:
Gasanov M.Z. MOLECULAR ASPECTS OF SARCOPENIA PATHOGENESIS IN CHRONOC KIDNEY DISEASE: INTEGRATED ROLE OF mTOR. Nephrology (Saint-Petersburg). 2018;22(5):9-16. (In Russ.) https://doi.org/10.24884/1561-6274-2018-22-5-9-16
Views:
1702
Email this article 